Strides Pharma gets USFDA EIR for Bengaluru plant

Strides Pharma gets USFDA EIR for Bengaluru plant. The company received an Establishment Inspection Report (EIR) following a USFDA audit of its Bengaluru facility. The EIR indicates no critical observations, signaling positive regulatory compliance. This outcome supports future export prospects to the US market.

📊 STOCKS: $STRAIT | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA